23.02.2018 | Onkologie | editorial | Ausgabe 1/2018
Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
- Zeitschrift:
- memo - Magazine of European Medical Oncology > Ausgabe 1/2018
Tipp
Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Anzeige
1.
Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95(6):691–8.
CrossRefPubMedPubMedCentral
2.
3.
4.
5.
6.
Mottet N, De SM, Briers E, Bourke L, Gillessen S, Grummet JP, et al. Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard. Eur Urol. 2017;
https://doi.org/10.1016/j.eururo.2017.09.029.
7.
Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–62.
CrossRefPubMed
8.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.
CrossRefPubMedPubMedCentral
9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.
CrossRefPubMedPubMedCentral
10.
11.
Sweeney C, Davis I et al. Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET), NCT02446405. 2018.
12.
Escudier B, Tannir N, McDermott D. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metatstatic renal cell carcinoma (mRCC), including IMDC risk and PDL-1 expression subgroups. 2018.
13.
Bellmunt J, Bajorin DF. Pembrolizumab for advanced urothelial carcinoma. N Engl J Med. 2017;376(23):2304–8.
PubMed
14.
Bellmunt J, de WR, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.
CrossRefPubMedPubMedCentral
15.
Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De GU, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017;
https://doi.org/10.1016/S0140-6736(17)33297-X.
16.
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
CrossRefPubMedPubMedCentral
17.
18.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77.
CrossRefPubMed
19.
Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61.
CrossRefPubMed
20.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.
CrossRefPubMedPubMedCentral
- Titel
- Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
- Autor:
-
MD Ursula M. Vogl
- Publikationsdatum
- 23.02.2018
- Schlagwort
- Onkologie
- DOI
- https://doi.org/10.1007/s12254-018-0393-1
- Verlag
- Springer Vienna
- Zeitschrift
- memo - Magazine of European Medical Oncology
An International Journal for Oncology and Haematology Professionals
Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076